Pharmacology
News
FDA OKs low-dose colchicine for broad CV indication
“The FDA approval of colchicine for patients with atherosclerotic disease is a huge signal that physicians need to be aware of inflammation as a...
News
Aspirin warning: Anemia may increase with daily use
“We found that low-dose aspirin also increased the risk of anemia during the trial, and this was most likely due to bleeding that was not...
News
Combo treatment eases nausea and vomiting of pregnancy
Some women have such severe nausea they are literally starving and so weak they are bedridden or even hospitalized.
News
‘Deprescribing’: Should some older adults shed their meds?
“The clinical inertia, or maintaining the status quo, unfortunately is a lot of times easier than having time-intensive conversations.”
Conference Coverage
New study backs up capecitabine dosing practice in metastatic BC
Study finds similar progression-free and overall survival in 7-day-on/7-day-off schedule, with fewer side effects than 14 days on, 7 days off.
Conference Coverage
Ticagrelor may reduce brain lesions after carotid stenting
There were also significantly fewer cases of a composite of adverse clinical events with ticagrelor versus clopidogrel, but no difference in rates...
News
New EULAR lupus recommendations advise using biologics, tapering steroids
The 2023 recommendations cover new treatment strategies with more ambitious goals, new data on adverse effects of chronic glucocorticoid use, and...
News
FDA OKs Injectafer for iron deficiency anemia in heart failure
“This new indication for Injectafer marks the first and only FDA approval of an intravenous iron replacement therapy for adult patients with heart...
Latest News
Abrocitinib remains effective at 96 weeks, in older as well as younger adults
The analysis stratified patients by age – 18-50 and over 50 years – and found that the sustained improvement with the JAK-1 selective inhibitor as...
Conference Coverage
Oral drug for brain tumor could change treatment landscape
Vorasidenib was associated with a significant delay in time to disease progression when compared with placebo, in a new study.